Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2273 • ACR Convergence 2023
Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
Vasileios Kyttaris¹, Tyler O'Malley², Giorgio Casaburi², Sudha Kumar² and Andrew Concoff³, ¹BIDMC, Boston, MA, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…
Abstract Number: 2291 • ACR Convergence 2023
Therapeutic Drug Monitoring (TDM) of Hydroxychloroquine in Whole Blood: Analysis of over 10,000 Patient Results Using Lab Developed Liquid Chromatography Tandem Mass Spectrometry
Jane Yang, Brett Holmquist, Rubio Punzalan and Kelly Chun, Labcorp, Calabasas, CA
Background/Purpose: Hydroxychloroquine (HCQ), a mainstay SLE therapy, improves survival and reduces flares. Therapeutic drug monitoring (TDM) may be useful in 1) identifying and improving adherence…
Abstract Number: 2307 • ACR Convergence 2023
Comparing Social Vulnerability Index to Area Deprivation Index to Patient Outcomes in SLE and Glucocorticoid Utilization
Avira Som¹, Lily McMorrow¹, Ling Chen¹, Deepali Sen², Elizabeth Baker³ and Alfred Kim⁴, ¹Washington University School of Medicine in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis, MO, ³Saint Louis University, St. Louis, MO, ⁴Washington University School of Medicine, St. Louis, MO
Background/Purpose: As shown in previous studies, outcomes in SLE are affected by social determinants of health which influence health care disparities. Evaluating health disparities through…
Abstract Number: 2323 • ACR Convergence 2023
An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health
Yu Huang¹, Lixia Yao², zhengkang Fan³, Jingchuan Guo¹ and Jiang Bian¹, ¹University of Florida, Gainesville, FL, ²Polygon Health Analytics LLC, Chalfont, PA, ³University of Florida, Gainsville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) has a relapsing-remitting course, with patients experiencing disease activity flares over time. Flares and prolonged disease activity are associated with…
Abstract Number: 2342 • ACR Convergence 2023
Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Aida Santos da Costa¹, Thomas Dörner², Andrea Grioni¹, Alexandre Avrameas¹, Ulrike Sommer¹, Rainer Hillenbrand¹, Valeria De Luca¹, Enrico Ferrero¹, Andre Nogueira da Costa¹, Isabelle Isnardi¹ and Stephen J Oliver¹, ¹Novartis Pharma AG, Basel, Switzerland, ²Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany
Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 2453 • ACR Convergence 2023
Development of a Hydroxychloroquine Retinopathy Prediction Score
April Jorge¹, Ronald Melles², Baijun Zhou¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Kaiser Permanente Northern California, Redwood City, CA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is an important medication for SLE and other rheumatic diseases, but its major adverse event is HCQ retinopathy. Weight-based HCQ dose is…
Abstract Number: 2527 • ACR Convergence 2023
Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…
Abstract Number: PP07 • ACR Convergence 2023
How “Coming Out” About My Lupus Diagnosis Allowed Me to Connect With Patients, Get Involved With Research, and Spread Awareness
Jamie Chieh Lo, School of Medicine, I-Shou University, Keelung, Taiwan
Background/Purpose: Ever since I started medical school, I have been advised to not talk about my experiences with SLE. Family, friends, and even professors have…
Abstract Number: 001 • 2023 Pediatric Rheumatology Symposium
Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System
Jordan Roberts, Anna Faino, Mersine Bryan, Jonathan Cogen and Esi Morgan, Seattle Children's Hospital, Seattle, WA
Background/Purpose: High rates of serious infection have beenreported in pediatric systemic lupus erythematosus (pSLE), but modern care practices including pneumococcal vaccination, changing corticosteroid use, and…
Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Rebecca Hetrick¹, Maria Pereira² and Marietta De Guzman³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
Abstract Number: 002 • 2023 Pediatric Rheumatology Symposium
Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression
Coziana Ciurtin¹, Junjie Peng¹, Pierre Donnes¹, Stacy Ardoin², Laura Schanberg³, Laura Lewandowski⁴, George A Robinson¹ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Nationwide Children's Hospital, Columbus, OH, ³Duke University Medical Center, Durham, NC, ⁴NIAMS, NIH, Bethesda, MD
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is associated with chronic inflammation and increased risk of atherosclerosis. The APPLE trial was a randomised, placebo-controlled trial of…
Abstract Number: 091 • 2023 Pediatric Rheumatology Symposium
Achieving Remission in Childhood-onset Systemic Lupus Erythematosus: Rapid Implementation of an EMR-integrated Dashboard to Measure Disease Activity and Remission Rates
Kaleo Ede¹, Nikita Goswami², Elisa Wershba², Michael Shishov², Samantha Casselman², Pierina Ortiz² and Vinay Vaidya², ¹Phoenix Children's Hosptial; University of Arizona College of Medicine- Phoenix, Phoenix, AZ, ²Phoenix Children's Hospital, Phoenix, AZ
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…
Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Emily Zhang¹, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan¹, Mindy Lo¹, Olha Halyabar², Melissa Hazen¹, Ezra Cohen³, Lauren Henderson¹, Siobhan Case⁴, Margaret Chang¹, Camille Frank¹, Ankana Daga¹, Jonathan Hausmann⁵, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma¹, Mia Chandler⁶, Fatma Dedeoglu¹, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁷, Mary Beth Son¹ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, ⁶Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Muriel Velez, Bryan Nicolalde, Kevin Moreno-Montenegro, Gabriela Carolina Carrera-Barriga, Camila Gallegos and Beatriz Leon, Universidad San Francisco de Quito, Quito, Ecuador
Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…
Abstract Number: 010 • 2023 Pediatric Rheumatology Symposium
Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation
Natoshia Cunningham¹, Michelle Adler², Ashley Danguecan³, Mallet Reid², Samantha Ely⁴, Mathew Reeves², Lawrence Ng³, Paris Moaf³, Sarah Mossad³, Tala El Tal³, Luana Flores Pereira³, Deborah Levy³, Linda Hiraki³, Jennifer Stinson³, Sarah Ahola Kohut³, Khalid Abulaban⁵, Elizabeth Kessler⁵, Stacy Allen⁵, Tamar Rubinstein⁶, Evin Rothschild⁶, Natalie Rosenwasser⁷, Kabita Nanda⁷, Susan Canny⁷, Emily Smitherman⁸, Livie Huie⁸, James Birmingham⁹, Allison Thompson¹⁰, Janel Thompson¹⁰, Miranda Moyer¹⁰, Emily Nguyen¹⁰, Angela Chapson¹⁰ and Andrea Knight³, ¹Michigan State University, Grand Rapids, MI, ²Michigan State University, East Lansing, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Wayne State University, Michigan State University, Detroit, MI, ⁵Helen DeVos Children's Hospital, Grand Rapids, MI, ⁶Children's Hospital at Montefiore, New York, NY, ⁷Seattle Children's Hospital, Seattle, WA, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Metro Health, Cleveland, ¹⁰Patient Co-Investigative Team
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is associated with fatigue, pain, and depressive symptoms that adversely impact health-related quality of life. The Treatment and Education…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].